Courtney Flaherty
Jan 2, 2025 · Courtney Flaherty works for OncLive.com. First-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.
Biosimilar Policy Roundup—September 2024
Oct 1, 2024 · New Policy Updates and Considerations for the Future. The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar to Eylea (aflibercept), for treating retinal …
Earlier Patent Litigation Could Accelerate US Biosimilar Market Entry
4 days ago · The biosimilar market could be accelerated through patent litigation reforms that expedite biosimilar market availability throughout the US, according to a study published in …
Biosimilars Gastroenterology Roundup: November 2024
Nov 30, 2024 · Market Insights. Skyrizi (risankizumab-rzaa) has officially dethroned Humira (reference adalimumab) as AbbVie’s top seller, less than 2 years after adalimumab biosimilars …
Equivalence Confirmed: CT-P41 Paves the Way for Affordable …
5 days ago · This study (NCT04757376), published in Osteoporosis International, was conducted to evaluate the equivalence of the biosimilar CT-P41 to US reference denosumab …
The Top 5 Biosimilar Articles for the Week of January 6
3 days ago · Number 5: The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with projections indicating strong uptake in biosimilars at the …
EMA Approves First Ustekinumab Biosimilar, Uzpruvo - Center for …
Jan 10, 2024 · The product was developed by Alvotech and will be marketed by STADA Arzneimittel as part of a 2019 exclusive commercialization agreement. Uzpruvo is expected to …
Study Confirms CT-P42 Therapeutic Equivalence to Reference …
Jan 6, 2025 · The randomized, active-controlled, double-masked study, published in Ophthalmology Retina, evaluated the efficacy and equivalence of the biosimilar CT-P42 to …
Celltrion Sets Sights on 2030 With Expanded Biosimilar Portfolio ...
Nov 6, 2024 · Currently, Celltrion USA has 6 biosimilars (infliximab, rituximab, trastuzumab, adalimumab, bevacizumab, on the US market, as well as Zymfentra, a novel product that …
Reducing Financial Toxicity in GI Cancer Care Through Biosimilars
Jan 5, 2025 · During a recent interview at an Institute for Value-Based Care ® event hosted by The American Journal of Managed Care ® and Moffitt Cancer Center, Tiago Biachi, MD, PhD, …